Topic
NS5B
About: NS5B is a research topic. Over the lifetime, 1314 publications have been published within this topic receiving 59534 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: The antiviral screening of viral strains indicated that compound 6a can be selected as promising tool in novel anti‐flaviviruses development as well as in vitro inhibitory activity against the HCV RNA‐dependent RNA polymerase (NS5B).
Abstract: With the aim of identifying novel lead compounds active against emergent human infectious diseases, a series of 2,3-dihydro-4H-pyridinone derivatives has been prepared and evaluated for antiviral activity. Compounds were evaluated in vitro in cell-based assays for cytotoxicity and against a wide spectrum of viruses. In the antiviral screening, several compounds showed to be fairly active against viruses belonging to the Flaviviridae family. The Pestiviruses (bovine viral diarrhoea virus) were inhibited by 4a cis (CC(50) > 100 μm; EC(50) = 14 μm), compounds 4c cis and 6a showed a significant activity against Flaviviruses (Yellow Fever Virus) (CC(50) > 100 μm; EC(50) = 18μm, CC(50) > 100 μm; EC(50) = 10 μm). Among these, compound 6a displayed great inhibitory activity against Hepaciviruses (hepatitis C virus) in replicon assay [CC(50) > 100 μm; EC(50) (1b) = 4 μm]. In vitro inhibitory activity against the HCV RNA-dependent RNA polymerase (NS5B) of title compounds is discussed. The antiviral screening of viral strains indicated that compound 6a can be selected as promising tool in novel anti-flaviviruses development.
9 citations
TL;DR: Estimation of the processing sites by determination of the N-terminal amino acid sequences of the processed products revealed that all the Cpro-2-dependent cleavages occurred at essentially identical sites to those reported for another HCV genotype, suggesting that C Pro-2 is a possible target for the development of a strain-independent anti-HCV agent.
9 citations
TL;DR: Previous therapy and failure of peg-IFN+RBV were not associated with an increase in DAA-targeting NS3 or NS5B RAVs that naturally exist in HIV co-infected subjects.
9 citations
TL;DR: The in vitro combination studies demonstrate that additive to synergistic antiviral effects are observed when ANA598 is combined with other anti-HCV agents having distinct mechanisms of action and nonoverlapping resistance profiles.
9 citations
TL;DR: This review outlines the main clinical data concerning novel NS5B polymerase inhibitors currently in pipeline, focusing on the ones that have completed a phase 2 trial.
Abstract: Introduction: Hepatitis C virus (HCV) infection might be the first chronic viral disease to be eradicated without the introduction of a prophylactic vaccine. This is essentially due to therapeutic ...
9 citations